Actively Recruiting
Discarded Bone Marrow for Hematology Research
Led by St. Jude Children's Research Hospital · Updated on 2026-05-05
50
Participants Needed
1
Research Sites
648 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objective of this study is to establish a mechanism to obtain discarded bone marrow-containing bone samples from hemoglobinopathy, as well as non-hemoglobinopathy individuals. The processing of samples will help to understand how best to manipulate HSPC's from hemoglobinopathy patients with gene therapy and gene technologies in the laboratory environment. It will also allow us to establish a reservoir of samples that can be studied in the future to assess cellular function and fitness for transplant. Secondary objectives * To develop gene transfer and gene editing strategies as potentially curative therapy for hemoglobinopathies (e.g. sickle cell disease (SCD) and β-thalassemia). * To develop a drug treatment strategy which elevates the expression of fetal hemoglobin to a potentially curative level for hemoglobinopathies. * To examine the biology of bone marrow cells isolated from patients with hemoglobinopathies.
CONDITIONS
Official Title
Discarded Bone Marrow for Hematology Research
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients of any age receiving orthopedic surgery that involves discarded bone marrow-containing bone
- Patients with homozygous S/S disease or double heterozygous S and beta-thalassemia who are 2 years or older
- Patients with HbE-beta-thalassemia or severe beta-thalassemia, including transfusion-dependent or severely anemic but relatively transfusion-independent cases
- Diagnosis confirmed by standard hematological parameters, red cell indices, hemoglobin electrophoresis, and quantitative HbF and HbA2 determination
You will not qualify if you...
- Active acute sickle cell disease symptoms such as painful crisis, acute chest syndrome, cerebrovascular events, or active infection
- Pregnancy
- Inability or unwillingness to provide written informed consent
- Platelet count less than 150,000/mm^3
- Neutrophil count less than 2000/mm^3, or less than 1000/mm^3 if on hydroxyurea therapy
- Prothrombin time greater than 17 seconds
- Partial thromboplastin time greater than 43 seconds
- History of excessive bleeding during previous procedures including surgery and dental extractions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
St. Jude Children's Research Hospital
Memphis, Tennessee, United States, 38105
Actively Recruiting
Research Team
S
Shannon McKinney-Freeman, Ph.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here